Concerto Biosciences
Cambridge
About Concerto Biosciences
Concerto Biosciences rebuilds microbial communities in, on, and around us to heal our bodies and our planet. Products that rebuild microbial communities do not yet exist because no one can map the vast inter-species interaction networks responsible for community behavior. Concerto’s cofounders therefore invented the first-ever ultra-high-throughput platform to experimentally measure millions of microbial interactions. Concerto maps interaction networks that reveal a new class of products called “ensembles”’combinations of microbes that work in concert to shepherd damaged microbial communities to health. The opportunities are enormous: Concerto will become the premier inventor of ensembles across medicine and agriculture, reinventing humanity’s relationship with microbes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $26.0M
- Funding stage: Early Stage Venture
- Last round: Non-Equity Assistance (Sep 2024)
- Website: concertobio.com
- Phone: [email protected]
Industries & Categories
Big Data, Biopharma, Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/concerto-biosciences-63897 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.